DNAprint Genomics (DNAG)

[worktoplay]

frog...Tony believes that the BIG money is in becoming a pharmaceutical themselves. Bear in mind that their business model for the Ovanome classifier alone, anticipates generating peak year income of $16 million, and to continue at that pace for several years. His point, though, is that that sum pales in comparison to the hundreds of millions or billions that could be made with laser guided drugs.

Secondly, you said:

On the other hand, a side benefit of the effort to create a classifier also renders other information. Information that can, if discovered early in the development process, actually influence the eventual drug. Perhaps making it more 'universal' in scope or conversely, more finely targeted to a specific trait or population group. While this is a beneficial outcome to the patients and the industry, it does not necessarily have a viable business application. It is obvious that while such a service would be beneficial to a drug manufacturer, if there is no associated classifier there will be no revenue stream for DNAP.

I would point out that in order to market a drug that is "finely targeted" to a specific trait or population group, you will absolutely need the classifier to identify the patient (target) from amongst the general population. In fact, the classifier would have to be a part of the FDA submission for approval to market the drug.

Later,
W2P